Osteoporosis in Thalassemia Major;Talasemi Majorde Osteoporoz

Turk Osteoporoz Dergisi

Volumn 18, Issue 3, 2012, Pages 89-91

  Yiǧitoǧlu, Pembe Hare ^a   Güzel, Rengin ^b  

^a NEAR EAST UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Osteoporosis; Thalassemia

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCIUM; ESTROGEN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ZINC;

BONE DEMINERALIZATION; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; HORMONE SUBSTITUTION; IRON CHELATION; IRON OVERLOAD; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; THALASSEMIA MAJOR; TREATMENT RESPONSE;

EID: 84876166927     PISSN: 21463816     EISSN: 21472653     Source Type: Journal    
DOI: 10.4274/tod.02411     Document Type: Review

References (22)

1. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998;103: 911-5.
2. Kidson-Gerber GL, Francis S, Lindeman R. Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic. Med J Aust 2008;188: 72-5.
3. Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev Hematol 2011;4: 353-66.
4. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L et al. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 2000;111: 461-6.
5. Gaudio A, Morabito N, Xourafa A, Macrì I, Meo A, Morgante S et al. Bisphosphonates in the treatment of thalassemia-associated osteoporosis. J Endocrinol Invest 2008;31: 181-4.
6. Mamtani M, Kulkarni H. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. OsteoporosInt 2010;21: 183-7.
7. Hamed HM, Galal A, Ghamrawy ME, Abd El Azeem K, Hussein IR, Abd- Elgawad MF. An SP1-binding site polymorphism in the COLIAI gene and osteoporosis in Egyptian patients with thalassemia major. Blood Coagul Fibrinolysis 2011;22: 81-5.
8. Chatterjee R, Bajoria R. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin 2009;33(Suppl 1): 136-8.
9. Scacchi M, Danesi L, Cattaneo A, Valassi E, PecoriGiraldi F, Argento C et al. Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. ClinEndocrinol (Oxf) 2008;69: 202-7.
10. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease. ClinEndocrinol (Oxf) 2003;58: 273-9.
11. Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. Panminerva Med 2009;51: 17-23.
12. Leung TF, Chu Y, Lee V, Cheng FW, Leung WK, Shing MM et al. Longterm effects of pamidronate in thalassemic patients with severe bone mineral density deficits. Hemoglobin 2009;33: 361-9.
13. Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with β thalassemia major. Bone 2011;48: 425-32.
14. Guzeloglu-Kayisli O, Cetin Z, Keser I, Ozturk Z, Tuncer T, Canatan D et al. Relationship between SP1 polymorphism and osteoporosis in betathalassemia major patients. PediatrInt 2008;50: 474-6.
15. Salah H, Atfy M, Fathy A, Atfy M, Mansor H, Saeed J. The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients. Immunol Invest 2010;39: 820-32.
16. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;21;5: 11.
17. Otrock ZK, Mahfouz RA, Charafeddine KM, Rayes RF, Zahed LF, Taher AT. Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Ann Hematol 2008;87: 947-8.
18. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A et al. Biphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 2002;13: 644-9.
19. Patiroǧlu T, Altuner Torun Y, Kula M, Karakükçü M. Treatment of thalassemia-induced osteoporosis with intermittent pamidronate infusions: two-year follow-up. Turk J Hematol 2008;25: 79-82.
20. Gilfillan CP, Strauss BJ, Rodda CP, Bowden DK, Kean AM, Obaid M et al. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 2006;79: 138-44.
21. Evran M. Beta talasemili hastalarda osteoporoz ve osteoporozteda visinde zoledronik asit kullanimi (Osteoporosis in Thalassemia Patients and Use of Zoledronic Acid in the Treatment of Osteoporosis, unpublished thesis). Adana: Çukurova Üniversitesi; 2005.
22. Yigitoglu PH, Guzel R, Evran M, Gurkan E. Use of Zoledronic Acid in Thalassemia-Induced Osteoporosis:Two Case Reports and Review of the Literature. Turk J Phys Med Rehab 2012;58: 154-8.